AUPH
Aurinia Pharmaceuticals Inc
$15.79
$0.00(0.00%)
52
Overall
65
Value
40
Tech
--
Quality
Market Cap
$1.97B
Volume
1.06M
52W Range
$6.83 - $16.54
Target Price
$17.00
Company Overview
| Mkt Cap | $1.97B | Price | $15.79 |
| Volume | 1.06M | Change | +0.00% |
| P/E Ratio | 342.6 | Open | $15.96 |
| Revenue | $216.2M | Prev Close | $15.79 |
| Net Income | $5.8M | 52W Range | $6.83 - $16.54 |
| Div Yield | N/A | Target | $17.00 |
| Overall | 52 | Value | 65 |
| Quality | -- | Technical | 40 |
No chart data available
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, focuses on delivering therapies to treat autoimmune diseases with unmet medical needs in the United States. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest News
Aurinia Pharmaceuticals to Acquire Kezar, Expanding Autoimmune Pipeline
TipRanks Auto-Generated Newsdesk•5 days ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Neumora Therapeutics, Inc. (NMRA) and Aurinia Pharmaceuticals (AUPH)
Christine Brown•8 days ago
Aurinia to Buy Kezar Life Sciences in Cash-and-CVR Autoimmune Deal
TipRanks Canadian Auto-Generated Newsdesk•9 days ago
Aurinia Reshapes C-Suite as Investor Kevin Tang Takes CEO Role Without Pay
TipRanks Canadian Auto-Generated Newsdesk•16 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AUPH | $15.79 | 0% | 1.06M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Aurinia Pharmaceuticals Inc Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW